Osteosarcoma is the most prevalent bone malignancy, characterized by locally aggressive growth and early metastatic potential in children and adolescents. The incidence rate of OS is two cases per million, with a 5-year survival rate of less than 68% under 14 years old in the United States [1]. Despite the advances in the treatment of OS, including surgical resection and the use of chemotherapy drugs such as cisplatin, methotrexate, and doxorubicin, the subsequent side effects, for example, myelosuppression, nephrotoxicity, cardiac issues, and neurotoxicity, profoundly reduce patients’ quality of life [2, 3].